---
title: Scouting for autoimmune / immunology assets | Biotech consulting
description: Identifying novel pharma assets available for in-licensing for a venture fund
---

[Case Studies Archive - Alacrita ](https://www.alacrita.com/case-studies)

# [Scouting for autoimmune / immunology assets | Biotech consulting](https://www.alacrita.com/case-studies/scouting-for-autoimmune-immunology-assets)

 Written by [Cort](https://www.alacrita.com/case-studies/author/cort) | Jul 10, 2024 2:32:37 PM

## Challenge:

A new venture fund reached out to Alacrita for support with identifying novel pharma assets available for in-licensing, for the purpose of founding a new start-up and enabling the further development of the asset for autoimmune or immunology indications. Modalities of interest included small molecules, gene therapies, or biologics and de-prioritized assets that were IND-ready through phase 3 clinical development were in scope.

## Solution:

Alacrita consultants worked closely with the client to identify a stream of opportunities for further evaluation. Given the stage of development of interest, commercial pipeline databases were primarily used as a starting point. Assets identified as potential candidates were selected for outreach and our consultants reviewed and analyzed non-confidential data requested and received from the asset owner to determine fit with client criteria. A high-level summary for each asset of interest was provided to the client to determine whether to enter into further discussions with the asset owner.

After 3 months of scouting, 95 assets had been identified that met the client’s search criteria and discussions with 15 asset owners had been initiated. Alacrita provided a final draft of the asset scouting database and met with the client to discuss our conclusions and next steps.

##### Explore Our Asset Scouting & In-Licensing Services

Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our [asset scouting support](https://www.alacrita.com/our-services/pharmaceutical-licensing-asset-scouting) is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.

[Learn more](https://www.alacrita.com/our-services/pharmaceutical-licensing-asset-scouting)

[View full post](https://www.alacrita.com/case-studies/scouting-for-autoimmune-immunology-assets)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Cort"
  },
  "dateModified" : "2024-07-10T14:33:09.953Z",
  "datePublished" : "2024-07-10T14:32:37Z",
  "headline" : "Scouting for autoimmune / immunology assets",
  "image" : {
    "@type" : "ImageObject",
    "height" : 711,
    "url" : "https://cdn2.hubspot.net/hubfs/3828687/Alacrita_April2019/Images/alacrita_how_we_can_help_due_dilligence.jpg",
    "width" : 2000
  },
  "mainEntityOfPage" : "https://www.alacrita.com/case-studies/scouting-for-autoimmune-immunology-assets",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Case Studies"
  }
}
```